Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Evaluation of Tissue from Patients with Prostate Cancer Identifies B7-H3 as an Androgen-Regulated, Broadly Expressed, Combinatorial Therapeutic Target. | Clin Cancer Res | 2026 | 42053993 | PubTator, text mining | PubMed |
| Trop2 immunoPET/CT in clinical practice: facts and challenges. | Drug Discov Today | 2026 | 42049133 | PubTator, text mining | PubMed |
| Antibody-Drug Conjugates in Gastrointestinal Oncology: Clinical Efficacy and Inpatient Toxicity Management. | J Pers Med | 2026 | 42042562 | PubTator, text mining | PubMed |
| TROP2-targeting antibody-drug conjugates in breast cancer and ovarian carcinoma: therapeutic advances and resistance mechanisms. | Cancer Drug Resist | 2026 | 42040770 | PubTator, text mining | PubMed |
| Sacituzumab Govitecan as an Effective Strategy for Sensitizing Chemoresistant HNSCC Cells to Senolytic Intervention. | bioRxiv | 2026 | 42039381 | PubTator, text mining | PubMed |
| Evolving antibody-drug conjugates in breast cancer from precision delivery to tumor microenvironment reprogramming. | J Hematol Oncol | 2026 | 42036664 | PubTator, text mining | PubMed |
| Radionuclide-based pharmaceuticals for breast cancer imaging: state of the art. | EJNMMI Radiopharm Chem | 2026 | 42035386 | PubTator, text mining | PubMed |
| Overcoming ADC resistance in advanced colorectal cancer by dual targeting of TROP2 and PERK to suppress Wnt/β-catenin signaling. | Cell Rep Med | 2026 | 42030933 | PubTator, text mining | PubMed |
| Targeting TROP-2 in treatment-resistant non-small cell lung cancer harboring the KRAS G12C mutation and TROP-2 upregulation: A case report. | Oncol Lett | 2026 | 42027638 | PubTator, text mining | PubMed |
| YAP1 Defines an Emergent, Plastic Population of Relapsed SCLC. | J Thorac Oncol | 2026 | 42019833 | PubTator, text mining | PubMed |
| Plasma extracellular vesicle proteomics nominates candidate biomarkers of 177Lu-PSMA-617 outcomes in metastatic prostate cancer patients. | Cell Rep Med | 2026 | 42013849 | PubTator, text mining | PubMed |
| Comparative analysis of therapeutic target protein expression in de novo and transformed small cell lung carcinomas using paired biopsy samples. | Lung Cancer | 2026 | 42013561 | PubTator, text mining | PubMed |
| B7-H3 Gene Expression Shapes Prognosis and Therapeutic Opportunities across Patient Groups with Prostate Cancer. | Clin Cancer Res | 2026 | 42012455 | PubTator, text mining | PubMed |
| Quantification of Antibody-Drug Conjugate Targets in Head and Neck Squamous Cell Carcinoma. | Mol Cancer Ther | 2026 | 42008736 | PubTator, text mining | PubMed |
| Prolonged KRAS-MAPK Inhibition Induces Interferon Signaling That Promotes Cell State Transition and Confers Therapeutic Vulnerabilities. | Cancer Res | 2026 | 42008116 | PubTator, text mining | PubMed |
| Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study. | Cancer Cell | 2026 | 41999747 | PubTator, text mining | PubMed |
| Charting the blueprint: a bibliometric analysis reveals future strategies in lung cancer targeted therapy (2003-2025). | J Thorac Dis | 2026 | 41988266 | PubTator, text mining | PubMed |
| Exposure-Response Analyses of Datopotamab Deruxtecan (Dato-DXd) in Patients with Hormone Receptor (HR) Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer. | J Clin Pharmacol | 2026 | 41987715 | PubTator, text mining | PubMed |
Concordance and prognostic value of antibody drug conjugate and checkpoint inhibition targets in matched bladder cancer specimens from transurethral resection of the bladder, radical cystectomy and lymphadenectomy. | Urol Oncol | 2026 | 41986174 | PubTator, text mining | PubMed |
| Antibody-Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond. | J Thorac Oncol | 2026 | 41985715 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=10